22 results about "Leptin" patented technology

The present disclosure provides methods of treating congenital generalized lipodystrophy using tirzepatide. The disclosure also provides methods for treating a disease in a patient characterized by leptin and leptin signaling deficiency.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

This invention discloses anti-leptin monoclonal antibodies and their applications, relating to the field of biotechnology. This invention develops anti-leptin monoclonal antibodies 2A122H7 and 6B62E3, which can effectively recognize leptin. The ELISA kits prepared using these monoclonal antibodies 2A122H7 and 6B62E3 include indirect ELISA and double-antibody sandwich ELISA kits, exhibiting high specificity and sensitivity for the tested samples, and are convenient, efficient, and cost-effective. This invention provides effective technical support for advancing research on the regulatory mechanisms of economic traits such as feed intake, fat deposition, and reproduction in poultry.

Methods for altering leptin resistance and the hormonal control of energy balance, and methods for treating obesity and diabetes, as well as promoting weight gain, using batotin and batotin inhibitors.

This application discloses the application of pyridostigmine in the preparation of drugs for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Validation was conducted using animal models of NAFLD induced by three different etiologies: methionine-choline deficiency diet, high-fat diet, and leptin gene knockout. Pyridostigmine significantly improved vagal nerve activity in the model animals (e.g., improving high-frequency and baroreflex sensitivity in heart rate variability), effectively corrected serum lipid metabolism disorders (reducing LDL cholesterol), alleviated hepatocyte damage (reducing ALT and AST), and at the histopathological level, reduced hepatic steatosis, decreased inflammatory cell infiltration, and inhibited collagen deposition, thereby achieving the prevention and treatment of NAFLD.

The present invention relates to modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of preventing, inducing, causing or increasing weight loss, treating obesity and / or treating metabolic syndrome utilizing the modified or polymer conjugated MetAP2 inhibitors. The present invention also relates to methods of improving insulin sensitivity and glycemic control, reducing insulin levels and / or improving leptin sensitivity utilizing the modified or polymer conjugated MetAP2 inhibitors.

This invention belongs to the field of biomedical technology and discloses a specific structural lipase inhibitor that promotes ATGL activation, its preparation method, and its application. The inhibitor is derived from grape leaves. Through optimized extraction processes, the lipase inhibitory activity is significantly improved. The compound composition and structural ratio of the inhibitor are directionally enriched and clarified, resulting in a product with stable activity and controllable quality. Experiments have confirmed that the lipase inhibitor described in this application can simultaneously inhibit fat absorption and activate ATGL, forming a dual mechanism of action of "inhibiting absorption" and "inhibiting storage." It reduces TG, TC, LDL-C, LP, and FFA, upregulates HDL-C, stabilizes leptin, reduces ghrelin, and increases CCK and PYY, thereby effectively regulating lipid metabolism, controlling weight, improving blood lipids, and stabilizing blood sugar, with high safety.

The present application discloses the use of Gastrodia extract in the preparation of products for promoting the secretion of adiponectin and / or inhibiting the secretion of leptin. A large number of experiments have confirmed that by using Gastrodia extract, the secretion of leptin is successfully inhibited, the secretion of adiponectin is promoted, and the ratio of leptin to adiponectin is reduced, showing the potential application value of Gastrodia extract in improving fat aging.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

Provided are compositions comprising leptin and methods of using the same to support weight loss. Also provided are modified leptins, including recombinant leptins, and methods of making and using the same.

Provided here are compositions for delivery of leptin to a cell. The compositions can comprise a proteo-lipid vehicle comprising a recombinant fusion-associated small transmembrane (FAST) polypeptide and a nucleic acid encoding leptin or a functional fragment thereof. Also provided are methods for using the compositions.

The invention provides a method and system for detecting the malignant degree of endometrial cancer cells, and the method comprises the following steps: judging the influence mechanism of leptin on the malignant degree of cancer cells by detecting parameters such as leptin concentration, JAK2 / STAT3 pathway activation degree, cell proliferation activity, migration and invasion ability and the like; the dynamic association between the leptin concentration change and the activation state of the JAK2 / STAT3 signal channel can be systematically evaluated, the regulation and control effect of the channel on the proliferation, migration and invasion ability of cancer cells is effectively quantified, and a scientific basis is provided for developing treatment schemes and drugs for endometrial cancer.

The invention belongs to the technical field of aquaculture, and discloses a composition targeting a leptin gene of micropterus salmoides and capable of improving the feed utilization rate as well as a preparation method and application of the composition. The composition is prepared from the following components in parts by weight: 1 to 30 parts of wax gourd polysaccharide, 5 to 35 parts of gamma-aminobutyric acid and 1 to 20 parts of siRNA. Through complementary preparation of wax gourd polysaccharide, gamma-aminobutyric acid and siRNA, triple effects of gene silencing, appetite promotion and metabolism enhancement are realized. According to the invention, a wax gourd polysaccharide water extraction and alcohol precipitation process, a siRNA chemical synthesis process and a double-phase embedding-gradient composite process are adopted, so that the stability and bioavailability of active ingredients are improved. By down-regulating leptin expression, appetite and feed utilization rate of the micropterus salmoides fed with high-sugar feed are enhanced, blood sugar and blood fat levels are reduced, growth of fish bodies is promoted, and the micropterus salmoides culture medium can be applied to the field of micropterus salmoides culture.

The invention discloses an anti-leptin monoclonal antibody 6B6 2E3 and application of the anti-leptin monoclonal antibody 6B6 2E3, and relates to the technical field of biology. The invention develops the anti-leptin monoclonal antibody 6B6 2E3, and the anti-leptin monoclonal antibody 6B6 2E3 can be used for effectively identifying leptin. The ELISA kit prepared by utilizing the monoclonal antibody 6B6 2E3 comprises indirect ELISA, and has the advantages of strong specificity and high sensitivity on a detection sample, convenient and efficient detection operation and low cost. Effective technical support is provided for research on regulation and control mechanisms of economic characters such as fowl ingestion, fat deposition and reproduction.

The invention discloses an application of 3-hydroxy o-aminobenzoic acid in preparation of fat-reducing and weight-reducing products. According to the present invention, the first research results show that the 3-hydroxyanthranilic acid can significantly improve the secretion amount of leptin in the mouse body and influence the food intake of the mouse so as to achieve the purposes of reducing the mouse body weight increase, reducing the mouse body weight and improving the mouse obesity; therefore, the 3-hydroxy o-aminobenzoic acid can be used for preparing a fat-reducing and weight-reducing product which is high in biological safety and does not cause any adverse reaction.

The application discloses application of leptin in preparation of a medicine for promoting hair growth, and belongs to the technical field of biological medicines. The leptin provided in the application is expressed in hair matrix cells of a growing hair follicle, activates a JAK-STAT signal path, and induces continuous proliferation of hair matrix cells, so as to promote the hair follicle to enter the growing period in advance, prolong the time length of the growing period of the hair follicle, promote differentiation of the hair matrix cells into keratinocytes, maintain continuous growth of the hair shaft, and further prolong the length of the hair shaft.

The present disclosure provides methods for treating, ameliorating, and / or preventing glucose metabolism disorder by administering a leptin active delivered to the central nervous system (CNS), and in particular to brain regions. Also provided are compositions, kits and systems for practicing the methods.

The invention discloses an application of a PD-L1 single-domain antibody in preparation of a preparation for promoting hair growth or preventing and treating alopecia, belongs to the technical field of biological medicines, and particularly discloses an effect of the PD-L1 single-domain antibody in regulation and control of expression of cytokines IL-6 and Leptin so as to activate a JAK-STAT signal channel and provides a new preparation source for treatment of non-scar alopecia. The invention further provides a preparation containing the PD-L1 single-domain antibody, the side effect of an existing medicine for treating alopecia can be overcome, the treatment effect is good, and after a subject takes the medicine for 3-4 times and 8 weeks after the medicine is stopped, hair growth at the original alopecia position still continues.

25HC3S choline and crystalline 25HC3S choline are described herein.Further disclosed herein is the pharmaceutical preparation of 25HC3S choline, for example, using crystalline 25HC3S choline, and the method of using it to treat or prevent diseases, such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic condition, autoimmune condition, inflammatory condition, neurological condition, Epstein-Barr virus-related proliferation and the condition related to fat accumulation and inflammation.Also provided is the method of preparing 25HC3S, including crystalline 25HC3S choline.

Several salts of 25HC3S are provided, including crystalline salts of 25HC3S. Pharmaceutical formulations of the disclosed salts and methods for using them to treat or prevent diseases, such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus-associated proliferation, and conditions associated with fat accumulation and inflammation, are also provided. Methods for preparing the disclosed salts are also provided.

The invention discloses an application of Muraculum gardroncarteri in preparation of a product for preventing and / or treating obesity and related diseases of the obesity, and particularly discloses an application of the Muraculum gardroncarteri in preparation of a product for preventing and / or treating obesity and related diseases of the obesity. The core of the invention lies in that it is found that the Muriaculum gardroncarteri bacterium has significant effects of preventing and treating obesity and related diseases, and the strain can inhibit body weight gain under high fat diet, reduce accumulation of abdominal fat and subcutaneous fat, improve dyslipidemia, reduce the level of total cholesterol (TCHO) and low density lipoprotein cholesterol (LDL-C) in serum, and improve the immunity of the human body, so that the Muriaculum gardroncarteri bacterium can be used for preventing and treating obesity and related diseases. Meanwhile, fatty degeneration and inflammatory response of the liver can be improved, and leptin resistance and insulin resistance can be improved.

The application discloses a probiotic microecological preparation for promoting height growth of children and application thereof, and is characterized by comprising at least one of a fermented Lactobacillus mui ZGG35 strain with a preservation number of CGMCC No. 37997 and a plant Lactobacillus lactis ZGG180 strain with a preservation number of CGMCC No. 37998. The fermented Lactobacillus mui ZGG35 and the plant Lactobacillus lactis ZGG180 are inoculated into a fermentation culture medium at a proportion of 15% in volume ratio to obtain lactic acid bacteria culture, and the ZGG35 bacterial liquid and / or the ZGG180 bacterial liquid is added into a freeze-drying agent to prepare the probiotic microecological preparation. The probiotic microecological preparation has the advantages that the levels of growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein, alkaline phosphatase, osteocalcin, type I procollagen amino-terminal propeptide, insulin, leptin and vitamin D in serum can be improved, and the levels of IL-6 and CTX-I can be reduced.